Form 4: Eliem Therapeutics Director, Simon Tate, Acquires 10,000 Stock Options
SEC Form 4 Filing
Director Simon Tate acquired 10,000 stock options in Eliem Therapeutics, Inc. on June 26, 2024.
Summary
- On June 26, 2024, Simon Tate, a director of Eliem Therapeutics, Inc., acquired 10,000 stock options at an exercise price of $7.89.
- These options vest on the earlier of June 26, 2025, or the day before the next annual meeting of stockholders, contingent upon continuous service.
- Following this transaction, Mr. Tate directly owns 10,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which doesn't inherently indicate positive or negative performance.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company directors.
Stakeholder Impact
- The acquisition of stock options by a director could potentially increase shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 06/26/2024 | Date of the transaction: Simon Tate acquired 10,000 stock options. |
| 06/26/2025 | Vesting date of the options, or the day immediately prior to the next annual meeting of stockholders, whichever is earlier, subject to continuous service. |
| 06/25/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.